Profound Medical Corp. said the China Food and Drug Administration approved its device Sonalleve for the noninvasive treatment of uterine fibroids.

Uterine fibroids are the most common noncancerous tumors of the female reproductive tract in women, according to the company.

The Canadian device-maker said the product enables more precise and incision-free removal of diseased tissue.

Profound Medical acquired the Sonalleve MR-HIFU business from Royal Philips in 2017.